An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

NCT00487435 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1166

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain
Osteoarthritis
Low Back Pain

Interventions

DRUG: Tapentadol (CG5503) Extended Release (ER)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]